36
Participants
Start Date
March 25, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
Trastuzumab deruxtecan + 5FU/LV
trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles 5-FU/LV: leucovorin 200 mg/m2 i.v., followed by 5-fluorouracil (5-FU) 2600 mg/m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
Trastuzumab deruxtecan + FLO
trastuzumab deruxtecan 5.4 mg/kg i.v., on day 1, Q3W for max 3 cycles plus 4 cycles FLO: oxaliplatin 85 mg/m2 and leucovorin 200 mg/m2, each as an i.v. infusion followed by 5-FU 2600 mg/ m2 as a 24-h continuous infusion on day 1, Q2W for 4 cycles
NOT_YET_RECRUITING
Charite Universitätsmedizin Berlin, Berlin
NOT_YET_RECRUITING
Hämatologisch-Onkologische Praxis Eppendorf (hope), Hamburg
NOT_YET_RECRUITING
Krankenhaus Nordwest GmbH Institut für Klinisch-Onkologische Forschung (IKF), Frankfurt am Main
NOT_YET_RECRUITING
Nationales Centrum für Tumorerkrankungen, Heidelberg
NOT_YET_RECRUITING
Klinikum rechts der Isar München der TU München, München
NOT_YET_RECRUITING
Universitätsklinikum Ulm, Ulm
NOT_YET_RECRUITING
Klinikum Nürnberg, Nuremberg
NOT_YET_RECRUITING
Klinikum Chemnitz gGmbH, Chemnitz
NOT_YET_RECRUITING
Universitätsmedizin Halle, Universitätsklinikum Halle (Saale), Halle
NOT_YET_RECRUITING
Universitätsklinikum Jena, Jena
RECRUITING
Universitätsklinikum Leipzig, Leipzig
Collaborators (1)
Daiichi Sankyo
INDUSTRY
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
OTHER